Regen Biopharma, Inc.Regen Biopharma, Inc.Regen Biopharma, Inc.

Regen Biopharma, Inc.

No trades
See on Supercharts
Market capitalization
‪2.13 M‬USD
−0.2397USD
‪1.02 M‬USD
‪236.56 K‬USD
‪3.75 M‬
Beta (1Y)
−0.89

About Regen Biopharma, Inc.

CEO
David Raymond Koos
Headquarters
La Mesa
Employees (FY)
1
Founded
2012
ISIN
US75886M3007
FIGI
BBG0072GHT40
Regen Biopharma, Inc. is a biotechnology company, which engages in the business of developing regenerative medical applications and advancing novel technologies through pre-clinical and Phase I and II clinical trials. It also focuses on mRNA and small molecule therapies for treating cancer and autoimmune disorders. The company was founded on April 24, 2012 and is headquartered in La Mesa, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of RGBP is 0.7000 USD — it hasn't changed in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Regen Biopharma, Inc. stocks are traded under the ticker RGBP.
RGBP stock is 0% volatile and has beta coefficient of −0.89. Check out the list of the most volatile stocks — is Regen Biopharma, Inc. there?
Yes, you can track Regen Biopharma, Inc. financials in yearly and quarterly reports right on TradingView.
RGBP stock has risen by 12.11% compared to the previous week, the month change is a 12.50% fall, over the last year Regen Biopharma, Inc. has showed a 67.89% decrease.
RGBP net income for the last quarter is ‪−349.76 K‬ USD, while the quarter before that showed ‪−280.24 K‬ USD of net income which accounts for −24.81% change. Track more Regen Biopharma, Inc. financial stats to get the full picture.
Today Regen Biopharma, Inc. has the market capitalization of ‪2.63 M‬, it has decreased by 13.33% over the last week.
No, RGBP doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, RGBP shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Regen Biopharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
RGBP reached its all-time high on Sep 3, 2014 with the price of 1500.0000 USD, and its all-time low was 0.0015 USD and was reached on Mar 12, 2020.
See other stocks reaching their highest and lowest prices.
As of Apr 19, 2024, the company has 1.00 employees. See our rating of the largest employees — is Regen Biopharma, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Regen Biopharma, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Regen Biopharma, Inc. stock shows the sell signal. See more of Regen Biopharma, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Regen Biopharma, Inc. EBITDA is ‪−345.86 K‬ USD, and current EBITDA margin is −290.39%. See more stats in Regen Biopharma, Inc. financial statements.